High Grade Neuroendocrine Carcinoma of the Uterine Cervix: Outcomes and the Role of Radiation and Chemotherapy - The University of Iowa Experience

Results: 36 cases with follow-up information were identified. The median age at diagnosis was 49 years (range 26 – 77). FIGO staging was IB1 for 14 pts (39%), IB2 for 3 (8%), II for 7 (19%), and 12 (34%) had stage III or higher. 17 pts (47.2%) underwent resection, 20 pts (56%) had radiation therapy (RT), and 27 pts (82%) received chemotherapy (ChT). The median survival (MS) for the entire cohort was 20.7 months (ms) with 23% 5year overall survival (5-OS) and 8% 10-year OS. Stage was a strong predictor of survival. Pts with stage IB1 or less had longer MS and 5-OS compared to those with higher stage (MS 42 vs. 11.1 ms, p=0.008, 5-OS 47 vs. 6%).